Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
1. A method of treating a gastrointestinal disease associated with increased eosinophils comprising administering to a subject in need thereof a therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, wherein the gastrointestinal disease associated with increased eosinophils is selected from the group consisting of sclerosing cholangitis, irritable bowel disease, ulcerative colitis, eosinophilic esophagitis, eosinophilic gastroenteritis, inflammatory bowel disease, eosinophilic colitis, gluten sensitivity, Cronkhite-Canada syndrome, and any combination thereof.
2. The method of claim 1 , wherein the pharmaceutically acceptable salt is (6R)-4, 5, 6, 7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate.
3. The method of claim 1 , further comprising measuring the level of eosinophils in the subject's peripheral blood, tissue, or a combination thereof.
4. The method of claim 3 , wherein the level of eosinophils is selected from the group consisting of at or above 100 cells per microliter, at or above 150 cells per microliter, at or above 200 cells per microliter, and at or above 300 cells per microliter.
5. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is from about 50 milligrams to about 1,500 milligrams per day.
6. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 300 milligrams per day.
7. The method of claim 1 , wherein the dexpramipexole or a pharmaceutically acceptable salt thereof is administered in a solid unit dose selected from a tablet or capsule.
8. The method of claim 1 , wherein administering comprises administering a fraction of the daily dose two or more times per day.
9. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is administered as an initial dosing regimen followed by a maintenance dosing regimen.
10. The method of claim 9 , wherein the initial dosing regimen is administered for about 1 week to about 12 weeks.
11. The method of claim 9 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the initial dosing regimen is from about 50 milligrams to about 1,500 milligrams per day.
12. The method of claim 9 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the maintenance dosing regimen is from about 50 milligrams to about 300 milligrams per day.
13. The method of claim 1 , further comprising an induction step comprising administering a second therapeutic agent.
14. The method of claim 13 , wherein the second therapeutic agent is capable of decreasing eosinophil levels and is selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a tyrosine kinase inhibitor, a fusion protein, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a chemotherapeutic agent and a combination thereof.
15. The method of claim 13 , wherein said induction step comprises administering the second therapeutic agent from about 1 week to about 6 months.
16. The method of claim 1 , wherein therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is administered via a route of administration selected from the group consisting of orally, by inhalation, intranasally, via intravenous administration, topically, and any combination thereof.
17. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of one or more secondary agents.
18. The method of claim 17 , wherein the secondary agent is selected from the group consisting of a glucocorticoid, a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a phenolic antioxidant, an anti-proliferative drug, a tyrosine kinase inhibitor, an anti-IL-5 or an anti-IL5 receptor monoclonal antibody, an anti-IL-13 or an anti-IL-13 receptor monoclonal antibody, an ant-IL-4 or an anti-IL-4 receptor monoclonal antibody, an anti-IgE monoclonal antibody, an anti-TSLP monoclonal antibody, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a TNF-α inhibitor, a fusion protein, a chemotherapeutic agent, and a combination thereof.
19. The method of claim 1 , wherein the gastrointestinal disease is eosinophilic gastroenteritis.
20. The method of claim 19 , wherein the pharmaceutically acceptable salt is (6R)-4, 5, 6, 7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate.
21. The method of claim 19 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is from about 50 milligrams to about 1,500 milligrams per day.
22. The method of claim 19 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 300 milligrams per day.
23. The method of claim 21 , wherein administering comprises administering a fraction of the daily dose two or more times per day.
24. The method of claim 19 , wherein the dexpramipexole or a pharmaceutically acceptable salt thereof is administered in a solid unit dose selected from a tablet or capsule.
25. The method of claim 19 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is administered as an initial dosing regimen followed by a maintenance dosing regimen.
26. The method of claim 25 , wherein the initial dosing regimen is administered for about 1 week to about 12 weeks.
27. The method of claim 25 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the initial dosing regimen is from about 50 milligrams to about 1,500 milligrams per day.
28. The method of claim 25 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the maintenance dosing regimen is from about 50 milligrams to about 300 milligrams per day.
29. The method of claim 19 , further comprising an induction step.
30. The method of claim 29 , wherein said induction step comprises administering a second therapeutic agent that is capable of decreasing eosinophil levels selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a tyrosine kinase inhibitor, a fusion protein, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a chemotherapeutic agent and a combination thereof.
31. The method of claim 29 , wherein said induction step is from about 1 week to about 6 months.
32. The method of claim 19 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is administered via a route of administration selected from the group consisting of orally, by inhalation, intranasally, via intravenous administration, topically, and any combination thereof.
33. The method of claim 19 , further comprising administering to the subject a therapeutically effective amount of one or more secondary agents.
34. The method of claim 33 , wherein the secondary agent is selected from the group consisting of a glucocorticoid, a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a phenolic antioxidant, an anti-proliferative drug, a tyrosine kinase inhibitor, an anti-IL-5 or an anti-IL5 receptor monoclonal antibody, an anti-IL-13 or an anti-IL-13 receptor monoclonal antibody, an anti-IL-4 or an anti-IL-4 receptor monoclonal antibody, an anti-IgE monoclonal antibody, an anti-TSLP monoclonal antibody, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a TNF-α inhibitor, a fusion protein, a chemotherapeutic agent, and a combination thereof.
35. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 75 milligrams per day.
36. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 100 milligrams per day.
37. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 150 milligrams per day.
38. The method of claim 19 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 75 milligrams per day.
39. The method of claim 19 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 100 milligrams per day.
40. The method of claim 19 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 150 milligrams per day.